- Home
- AVDX vs DAWN Comparison
AVDX vs DAWN Comparison
Compare AVDX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- DAWN
- Stock Information
- Founded
- AVDX 2000
- DAWN 2018
- Country
- AVDX United States
- DAWN United States
- Employees
- AVDX N/A
- DAWN N/A
- Industry
- AVDX EDP Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- DAWN Health Care
- Exchange
- AVDX Nasdaq
- DAWN Nasdaq
- Market Cap
- AVDX 2.0B
- DAWN 658.9M
- IPO Year
- AVDX 2021
- DAWN 2021
- Fundamental
- Price
- AVDX $9.85
- DAWN $6.88
- Analyst Decision
- AVDX Hold
- DAWN Strong Buy
- Analyst Count
- AVDX 15
- DAWN 7
- Target Price
- AVDX $10.04
- DAWN $31.57
- AVG Volume (30 Days)
- AVDX 2.5M
- DAWN 1.3M
- Earning Date
- AVDX 07-30-2025
- DAWN 07-29-2025
- Dividend Yield
- AVDX N/A
- DAWN N/A
- EPS Growth
- AVDX N/A
- DAWN N/A
- EPS
- AVDX 0.01
- DAWN N/A
- Revenue
- AVDX $441,284,000.00
- DAWN $161,922,000.00
- Revenue This Year
- AVDX $5.56
- DAWN $17.98
- Revenue Next Year
- AVDX $10.01
- DAWN $49.50
- P/E Ratio
- AVDX $1,101.11
- DAWN N/A
- Revenue Growth
- AVDX 10.46
- DAWN N/A
- 52 Week Low
- AVDX $6.61
- DAWN $6.08
- 52 Week High
- AVDX $12.93
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- AVDX 71.39
- DAWN 57.28
- Support Level
- AVDX $9.83
- DAWN $6.52
- Resistance Level
- AVDX $9.81
- DAWN $6.95
- Average True Range (ATR)
- AVDX 0.02
- DAWN 0.25
- MACD
- AVDX -0.02
- DAWN 0.04
- Stochastic Oscillator
- AVDX 95.00
- DAWN 90.79
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.